Prognostic value of positron emission tomography myocardial perfusion imaging beyond traditional cardiovascular risk factors

Systematic review and meta-analysis

Konstantinos C. Siontis, Panithaya Chareonthaitawee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Despite substantive growth in utilization of positron emission tomography (PET) myocardial perfusion imaging (MPI), evidence on its prognostic value is limited. We aimed to comprehensively evaluate the prognostic literature of PET perfusion measures according to the most recent American Heart Association recommendations for assessment of novel cardiovascular biomarkers. Methods: We searched the literature for studies reporting associations of PET MPI measures and outcomes in patients with known or suspected coronary artery disease. We documented hazard ratios (HR) and 95% confidence intervals (CI) of association effects and quantitatively synthesized them with random-effects meta-analyses. Discrimination, calibration and risk reclassification after addition of PET MPI measures to standard prognostic models were documented. Results: We identified 20 eligible studies with median n. = 551 patients. In meta-analyses, the extents of ischemic and scarred myocardium were significantly associated with cardiac death. Meta-analyses of multivariate estimates for abnormal summed stress score ≥. 4 and myocardial perfusion reserve <. 2 revealed significant associations with major adverse cardiovascular events [HR (95% CI) 2.30 (1.53-3.44) and 2.11 (1.33-3.36), respectively]. Changes in model discrimination, calibration or risk reclassification were reported in 5 studies (8 prognostic evaluations). There were marginal improvements in discrimination based on C index and no improvements in model calibration. Net reclassification index ranged from 9.8% to 14.2% and risk classification was significantly improved in 4/5 prognostic evaluations. Conclusions: PET MPI measures were strongly associated with adverse patient outcomes. Risk classification was more consistently improved than discrimination and calibration after addition of PET MPI measures, but reporting of such metrics was overall limited.

Original languageEnglish (US)
Pages (from-to)54-59
Number of pages6
JournalIJC Heart and Vasculature
Volume6
DOIs
StatePublished - Mar 1 2015

Fingerprint

Myocardial Perfusion Imaging
Positron-Emission Tomography
Meta-Analysis
Calibration
Perfusion
Confidence Intervals
Coronary Artery Disease
Myocardium
Biomarkers
Outcome Assessment (Health Care)
Growth

Keywords

  • Calibration
  • Discrimination
  • Myocardial perfusion imaging
  • Positron emission tomography
  • Prognosis
  • Risk reclassification

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prognostic value of positron emission tomography myocardial perfusion imaging beyond traditional cardiovascular risk factors : Systematic review and meta-analysis. / Siontis, Konstantinos C.; Chareonthaitawee, Panithaya.

In: IJC Heart and Vasculature, Vol. 6, 01.03.2015, p. 54-59.

Research output: Contribution to journalArticle

@article{97809a7d65b04479b12856a87bf00aac,
title = "Prognostic value of positron emission tomography myocardial perfusion imaging beyond traditional cardiovascular risk factors: Systematic review and meta-analysis",
abstract = "Background: Despite substantive growth in utilization of positron emission tomography (PET) myocardial perfusion imaging (MPI), evidence on its prognostic value is limited. We aimed to comprehensively evaluate the prognostic literature of PET perfusion measures according to the most recent American Heart Association recommendations for assessment of novel cardiovascular biomarkers. Methods: We searched the literature for studies reporting associations of PET MPI measures and outcomes in patients with known or suspected coronary artery disease. We documented hazard ratios (HR) and 95{\%} confidence intervals (CI) of association effects and quantitatively synthesized them with random-effects meta-analyses. Discrimination, calibration and risk reclassification after addition of PET MPI measures to standard prognostic models were documented. Results: We identified 20 eligible studies with median n. = 551 patients. In meta-analyses, the extents of ischemic and scarred myocardium were significantly associated with cardiac death. Meta-analyses of multivariate estimates for abnormal summed stress score ≥. 4 and myocardial perfusion reserve <. 2 revealed significant associations with major adverse cardiovascular events [HR (95{\%} CI) 2.30 (1.53-3.44) and 2.11 (1.33-3.36), respectively]. Changes in model discrimination, calibration or risk reclassification were reported in 5 studies (8 prognostic evaluations). There were marginal improvements in discrimination based on C index and no improvements in model calibration. Net reclassification index ranged from 9.8{\%} to 14.2{\%} and risk classification was significantly improved in 4/5 prognostic evaluations. Conclusions: PET MPI measures were strongly associated with adverse patient outcomes. Risk classification was more consistently improved than discrimination and calibration after addition of PET MPI measures, but reporting of such metrics was overall limited.",
keywords = "Calibration, Discrimination, Myocardial perfusion imaging, Positron emission tomography, Prognosis, Risk reclassification",
author = "Siontis, {Konstantinos C.} and Panithaya Chareonthaitawee",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.ijcha.2015.01.005",
language = "English (US)",
volume = "6",
pages = "54--59",
journal = "IJC Heart and Vasculature",
issn = "2352-9067",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Prognostic value of positron emission tomography myocardial perfusion imaging beyond traditional cardiovascular risk factors

T2 - Systematic review and meta-analysis

AU - Siontis, Konstantinos C.

AU - Chareonthaitawee, Panithaya

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background: Despite substantive growth in utilization of positron emission tomography (PET) myocardial perfusion imaging (MPI), evidence on its prognostic value is limited. We aimed to comprehensively evaluate the prognostic literature of PET perfusion measures according to the most recent American Heart Association recommendations for assessment of novel cardiovascular biomarkers. Methods: We searched the literature for studies reporting associations of PET MPI measures and outcomes in patients with known or suspected coronary artery disease. We documented hazard ratios (HR) and 95% confidence intervals (CI) of association effects and quantitatively synthesized them with random-effects meta-analyses. Discrimination, calibration and risk reclassification after addition of PET MPI measures to standard prognostic models were documented. Results: We identified 20 eligible studies with median n. = 551 patients. In meta-analyses, the extents of ischemic and scarred myocardium were significantly associated with cardiac death. Meta-analyses of multivariate estimates for abnormal summed stress score ≥. 4 and myocardial perfusion reserve <. 2 revealed significant associations with major adverse cardiovascular events [HR (95% CI) 2.30 (1.53-3.44) and 2.11 (1.33-3.36), respectively]. Changes in model discrimination, calibration or risk reclassification were reported in 5 studies (8 prognostic evaluations). There were marginal improvements in discrimination based on C index and no improvements in model calibration. Net reclassification index ranged from 9.8% to 14.2% and risk classification was significantly improved in 4/5 prognostic evaluations. Conclusions: PET MPI measures were strongly associated with adverse patient outcomes. Risk classification was more consistently improved than discrimination and calibration after addition of PET MPI measures, but reporting of such metrics was overall limited.

AB - Background: Despite substantive growth in utilization of positron emission tomography (PET) myocardial perfusion imaging (MPI), evidence on its prognostic value is limited. We aimed to comprehensively evaluate the prognostic literature of PET perfusion measures according to the most recent American Heart Association recommendations for assessment of novel cardiovascular biomarkers. Methods: We searched the literature for studies reporting associations of PET MPI measures and outcomes in patients with known or suspected coronary artery disease. We documented hazard ratios (HR) and 95% confidence intervals (CI) of association effects and quantitatively synthesized them with random-effects meta-analyses. Discrimination, calibration and risk reclassification after addition of PET MPI measures to standard prognostic models were documented. Results: We identified 20 eligible studies with median n. = 551 patients. In meta-analyses, the extents of ischemic and scarred myocardium were significantly associated with cardiac death. Meta-analyses of multivariate estimates for abnormal summed stress score ≥. 4 and myocardial perfusion reserve <. 2 revealed significant associations with major adverse cardiovascular events [HR (95% CI) 2.30 (1.53-3.44) and 2.11 (1.33-3.36), respectively]. Changes in model discrimination, calibration or risk reclassification were reported in 5 studies (8 prognostic evaluations). There were marginal improvements in discrimination based on C index and no improvements in model calibration. Net reclassification index ranged from 9.8% to 14.2% and risk classification was significantly improved in 4/5 prognostic evaluations. Conclusions: PET MPI measures were strongly associated with adverse patient outcomes. Risk classification was more consistently improved than discrimination and calibration after addition of PET MPI measures, but reporting of such metrics was overall limited.

KW - Calibration

KW - Discrimination

KW - Myocardial perfusion imaging

KW - Positron emission tomography

KW - Prognosis

KW - Risk reclassification

UR - http://www.scopus.com/inward/record.url?scp=84930616628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930616628&partnerID=8YFLogxK

U2 - 10.1016/j.ijcha.2015.01.005

DO - 10.1016/j.ijcha.2015.01.005

M3 - Article

VL - 6

SP - 54

EP - 59

JO - IJC Heart and Vasculature

JF - IJC Heart and Vasculature

SN - 2352-9067

ER -